846 related articles for article (PubMed ID: 25702254)
1. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156 Suppl 1():3-23. PubMed ID: 26039413
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Dec; 156 Suppl 2():3-24. PubMed ID: 26667111
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
5. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867
[TBL] [Abstract][Full Text] [Related]
6. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2018 Feb; 159(Suppl 1):3-23. PubMed ID: 29478339
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
Hunyady B; Abonyi M; Csefkó K; Gervain J; Haragh A; Horváth G; Jancsik V; Makkai E; Müller Z; Ribiczey P; Sipos B; Szabó O; Szalay F; Szentgyörgyi L; Tornai I; Újhelyi E; Varga M; Weisz G; Makara M
Orv Hetil; 2016 Aug; 157(34):1366-74. PubMed ID: 27546804
[TBL] [Abstract][Full Text] [Related]
8. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
[TBL] [Abstract][Full Text] [Related]
9. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
11. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
[TBL] [Abstract][Full Text] [Related]
13. [Financial burden of hepatitis C infection and its treatment].
Makara M; Hunyady B
Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Yu ML
J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
[TBL] [Abstract][Full Text] [Related]
15. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
16. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
18. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
19. [New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Horváth G; Halász T; Makara M; Hunyady B
Orv Hetil; 2015 May; 156(21):841-8. PubMed ID: 26038991
[TBL] [Abstract][Full Text] [Related]
20. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
